` CLOV (Clover Health Investments Corp) vs S&P 500 Comparison - Alpha Spread

CLOV
vs
S&P 500

Over the past 12 months, CLOV has significantly outperformed S&P 500, delivering a return of 296% compared to the S&P 500's 12% growth.

Stocks Performance
CLOV vs S&P 500

Loading
CLOV
S&P 500
Add Stock

Performance Gap
CLOV vs S&P 500

Loading
CLOV
S&P 500
Difference

Performance By Year
CLOV vs S&P 500

Loading
CLOV
S&P 500
Add Stock

Competitors Performance
Clover Health Investments Corp vs Peers

Clover Health Investments Corp
Glance View

Market Cap
1.8B USD
Industry
Health Care

Clover Health Investments Corp. embarked on a mission to transform the healthcare landscape with its innovative approach as a next-generation Medicare Advantage insurer. Born out of the need to reduce inefficiencies and enhance care, Clover Health uses its proprietary technology platform, the Clover Assistant, to arm physicians with data-driven insights that facilitate informed decision-making at the point of care. By integrating technology with healthcare delivery, Clover targets not only the evident administrative wastage but also addresses the structural challenges faced by patients and providers alike. This unique integration of digital tools with a traditional insurance model sets Clover apart in an industry ripe for disruption. Revenue for Clover Health primarily comes from Medicare Advantage premiums, where it competes by offering cost-effective plans combined with improved service. The company augments its financial model through government reimbursements tied to patient outcomes and the quality of care. Central to this strategy is the effective use of data analytics to manage patient care, reduce medical costs, and improve customer satisfaction. This alignment of financial incentives—lowering costs while enhancing patient outcomes—fuels Clover’s growth narrative, positioning it as a key player in reshaping how Medicare Advantage operates at the intersection of technology and healthcare delivery.

CLOV Intrinsic Value
3.3 USD
Overvaluation 7%
Intrinsic Value
Price
Back to Top